Focused On-demand Library for Rabenosyn-5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

110 kDa protein; FYVE finger-containing Rab5 effector protein rabenosyn-5; RAB effector RBSN; Zinc finger FYVE domain-containing protein 20

Alternative UPACC:

Q9H1K0; B4DWY8; C9J4P5; Q3KP30; Q59EY8; Q8NAQ1


Rabenosyn-5, known for its alternative names such as 110 kDa protein, FYVE finger-containing Rab5 effector protein rabenosyn-5, RAB effector RBSN, and Zinc finger FYVE domain-containing protein 20, plays a pivotal role in cellular processes. It acts as a Rab4/Rab5 effector in early endocytic membrane fusion and trafficking of recycling endosomes, essential for endosome fusion and lysosomal trafficking of CTSD/cathepsin D. Furthermore, it facilitates the recycling of transferrin and its receptor directly from early endosomes to the plasma membrane, binding to phospholipid vesicles containing phosphatidylinositol 3-phosphate.

Therapeutic significance:

Understanding the role of Rabenosyn-5 could open doors to potential therapeutic strategies, particularly in enhancing lysosomal trafficking and membrane recycling processes, which are crucial in maintaining cellular homeostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.